Blautia argi ameliorates the motor impairment of 6-Hydroxydopamine hydrochloride-induced Parkinson’s disease rat model
Objective: To evaluate the potential protective effects of Blautia argi on a 6-Hydroxydopamine (6-OHDA)-induced rat model of Parkinson's disease (PD). Background: PD is a common…Clinical and neuroimaging factors associated with survival in Multiple System Atrophy
Objective: To assess clinical and neuroimaging factors associated with survival in a cohort of patients with a final clinical diagnosis of Multiple System Atrophy (MSA)…Correlation of lmaging Markers with Clinical Features in Multiple System Atrophy Patients
Objective: This study aims to investigate the correlation between visually assessable imaging markers and their clinical symptoms in Multiple System Atrophy (MSA) patients. Background: MSA is…Remotely-deployed gamification intervention to increase physical activity in Parkinson’s Disease
Objective: To describe a remote, behavioral intervention designed to increase daily steps in Veterans with PD and report interim results from an ongoing clinical trial…Movement disorders in Brain Sagging Syndrome- A Systematic Review
Objective: Objective: This study aims to systematically review the array of movement disorders observed in patients diagnosed with brain sagging syndrome (BSS) secondary to spontaneous…Identification of Allosteric GCase Correctors Using Revenir™ for the Treatment of GBA1-Parkinson’s Disease
Objective: To identify novel non-inhibitory allosteric correctors of GCase using Congruence Therapeutic’s in silico proprietary drug discovery engine, Revenir™ Background: GBA1 encoding for glucocerebrosidase (GCase)…Safety and tolerability of opicapone in Parkinson’s Disease: from early-stage (EPSILON study) to late-stage (BIPARK studies)
Objective: To compare the safety and tolerability of once-daily opicapone (OPC) 50mg as add-on to stable levodopa/dopa decarboxylase inhibitor (L-DOPA/DDCI) therapy in patients from early…Rationale and Design of the Slowing Parkinson’s Early through Exercise Dosage – United Kingdom (Slow-SPEED-UK) Trial
Objective: Slow-SPEED-UK is a randomized controlled trial investigating the effects of an app-based exercise program on individuals at higher risk of Parkinson’s Disease (PD). Background:…Changes in Gut Microbiome of Parkinson’s disease Patients using Photobiomodulation Therapy
Objective: To assess changes in the gut microbiome composition in a small cohort of clinical trial participants using photobiomodulation (light therapy) over a five-year period…Effect of the mGlu2 positive allosteric modulator biphenyl-indanone A on parkinsonian disability in the 6-hydroxydopamine-lesioned rat
Objective: To evaluate the effect of biphenyl-indanone A (BINA), a metabotropic glutamate 2 (mGlu2) receptor positive allosteric modulator (PAM), on parkinsonian disability in the 6-OHDA-lesioned…
- « Previous Page
- 1
- …
- 71
- 72
- 73
- 74
- 75
- …
- 1554
- Next Page »